SCYNEXIS (NASDAQ:SCYX) Stock Price Crosses Below 200 Day Moving Average – Here’s Why

Posted by James Quigley on Feb 22nd, 2025

SCYNEXIS, Inc. (NASDAQ:SCYX – Get Free Report) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.33 and traded as low as $1.07. SCYNEXIS shares last traded at $1.07, with a volume of 105,478 shares trading hands.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of SCYNEXIS from a “sell” rating to a “hold” rating in a research note on Friday, November 8th.

View Our Latest Report on SCYX

SCYNEXIS Stock Down 3.2 %

The company’s 50 day moving average price is $1.13 and its 200 day moving average price is $1.33. The firm has a market capitalization of $40.61 million, a price-to-earnings ratio of -1.45 and a beta of 1.52.

Institutional Investors Weigh In On SCYNEXIS

Institutional investors and hedge funds have recently made changes to their positions in the stock. Two Sigma Securities LLC acquired a new stake in shares of SCYNEXIS during the fourth quarter worth $25,000. XTX Topco Ltd acquired a new stake in shares of SCYNEXIS during the third quarter worth $25,000. Millennium Management LLC acquired a new stake in shares of SCYNEXIS during the fourth quarter worth $31,000. Jane Street Group LLC purchased a new position in shares of SCYNEXIS during the fourth quarter worth $32,000. Finally, JPMorgan Chase & Co. purchased a new position in shares of SCYNEXIS during the fourth quarter worth $49,000. 54.37% of the stock is currently owned by institutional investors and hedge funds.

SCYNEXIS Company Profile

(Get Free Report)

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.